MRUS News and Press, Merus N.V. From 05/14/20

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers – – MCLA-117 demonstrates limited clinical activity in Phase 1 trial – – Extensive panel of novel CD3 bispecifi...

Merus (NASDAQ: MRUS ): Q1 GAAP EPS of -$0.68 beats by $0.01 . More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...

MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra, M.D. to succeed Russell Greig, Ph.D. as Chairman and Paolo Pucci Nominated for Appointment to Merus Board of Directors UTRECHT, The Ne...

Merus (NASDAQ: MRUS ): FY GAAP EPS of -$2.28 misses by $0.55 . More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Shares of Merus NV (MRUS) have fallen by 16% since my initial article was published in May of 2017, in which we touched on potential advantages of its Biclonics platform technology and multiple assets in the clinic. Shares have fallen by 7% since my February 2018 update piece. While, in ...

Merus's ( MRUS +1.8% ) CEO, Ton Logtenberg,  will step down, effective December 31, 2019; however, he will remain on as a senior advisor during the transition over the next year. More news on: Merus N.V., Healthcare stocks news, Read more ...

— Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer — — Ton Logtenberg, Ph.D., to step down after 16 years of leadership — — Transition to occur December 31, 2019 — UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2019 ...